With this in mind we used selective CK2 and DNA-PK inhibitors to evaluate whether the anti-proliferative and pro-apoptotic effects of CK2 inhibition involve DNA-PK and its target H2AX in CCA. Here, PRKDC is linked to cholangiocarcinoma.